Tiflorex

Tiflorex

Tiflorex

Never marketed appetite suppressant

Tiflorex (TFX), formerly known as flutiorex, is a stimulant[citation needed] amphetamine that was under development as an appetite suppressant in the 1970s,[1][2] but appears to have been abandoned. It is structurally related to fenfluramine and 4-MTA.

Quick Facts Clinical data, ATC code ...

Tiflorex went to phase II clinical trials. The extended release formulation "TFX-SR" produced significant suppression of appetite. It also caused slightly more sleep disturbances and headaches than placebo, as well as mydriasis and a self-reported decrease in arousal. It had little effect on heart rate.[2]

Tifluorex is claimed to be a more potent anorectic than fenfluramine, with twice its potency in humans[2] and 4 times its potency in rats.[3]

Pharmacology

Pharmacodynamics

The mechanism of action of tiflorex has apparently never been studied. Similar compounds such as fenfluramine, norfenfluramine and 4-MTA act as selective serotonin releasing agents and 5-HT2 receptor agonists. Fenfluramine in particular causes very similar side effects and appetite suppression at therapeutically relevant doses.

Pharmacokinetics

In rats, tiflorex is rapidly N-dealkylated to norflutiorex. Both tiflorex and norflutiorex appear to be excreted in urine.[1]

Synthesis

Patent:[4]

The Rosenmund reduction of 3-(trifluoromethylthio)benzoyl chloride [51748-28-8] (1) gave 3-((trifluoromethyl)thio)benzaldehyde [51748-27-7] (2). Henry reaction with nitroethane led to 1-(2-nitroprop-1-en-1-yl)-3-[(trifluoromethyl)sulfanyl]benzene [176242-84-5] (3). With the aid of iron catalyst in concentrated HCl acid there occurred FGI into 1-(3'-trifluoromethylthiophenyl)-2-propanone, CID:21325269 (4'). Reductive amination with ethylamine and formic acid as the reductant completed the synthesis of tiflorex (5).

References

  1. [1]
    Giudicelli JF, Richer C, Berdeaux A (February 1976). "Preliminary assessment of flutiorex, a new anorectic drug, in man". British Journal of Clinical Pharmacology. 3 (1): 113–21. doi:10.1111/j.1365-2125.1976.tb00578.x. PMC 1428817. PMID 788737.
  2. [2]
    Silverstone T, Fincham J, Plumley J (April 1979). "An evaluation of the anorectic activity in man of a sustained release formulation of tiflorex". British Journal of Clinical Pharmacology. 7 (4): 353–6. doi:10.1111/j.1365-2125.1979.tb00945.x. PMC 1429648. PMID 444355.
  3. [3]
    Stuart S (2013-09-11). Abstracts: Sixth International Congress of Pharmacology. Elsevier. ISBN 9781483152530.
  4. [4]
    Don P. R. L. Giudicelli & Henry Najer, U.S. patent 4,148,923 (1979 to Synthelabo SA).
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Tiflorex, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.